Olyx Participates in Bio Europe 2020... "Meetings with Global Pharmaceutical Companies"

[Asia Economy Reporter Hyunseok Yoo] Olig, a company developing various intractable disease treatments based on RNA interference technology, announced that it will participate in Bio-Europe 2020, held online from the 26th to the 29th, to introduce its platform technology and pipeline status. It will also hold meetings to explore the possibility of technology exports with major global big pharma companies.

Earlier this month, Olig signed a technology transfer contract worth up to 900 billion KRW with the French ophthalmology specialist company Th??. Olig received meeting proposals from more than 50 global companies, including the top 5 large pharmaceutical companies worldwide in sales. Through live meetings, they plan to discuss partnering for joint research.

In addition, Olig plans to meet with global leading companies related to dermatology to promote the license-out (technology export) of the hypertrophic scar treatment (OLX101A), for which it applied for Phase 2 clinical trial approval from the US FDA last month. It will actively promote building partnerships with global pharmaceutical companies and attracting investment, including conducting IR with multiple US investment firms.

At this conference, Olig will introduce the development status of its major pipelines, including the hypertrophic scar treatment, treatments for subretinal fibrosis and age-related macular degeneration (AMD), as well as liver disease treatments using the GalNAc platform technology. The goal is to pioneer markets through technology transfers in the Americas, Europe, and Asia regions.

In particular, the hypertrophic scar treatment (OLX101A) and treatments for dry age-related macular degeneration and subretinal fibrosis (OLX301A/D) that Olig will introduce currently have no approved treatments worldwide for their target diseases. The company expects that if the development of these programs progresses and they are commercialized, they will have value as first-in-class treatments.

After transferring global rights to Th?? earlier this month, Olig also plans meetings with pharmaceutical companies in the Asia region to export the Asia-Pacific regional rights of its ophthalmic disease treatments (OLX301A/D), which it still holds.

Lee Dong-ki, CEO of Olig, said, “The recent technology transfer contract with Th?? once again proved Olig’s technological capabilities, and we expect this conference to be an opportunity to strengthen our position in the RNA therapeutics market.”

Bio-Europe 2020, marking its 26th year, is the largest biotech conference in Europe, providing networking opportunities for partnerships among biotech companies, high-level corporate presentations, and exhibition sessions. As of last year, more than 4,300 stakeholders from over 2,300 companies in related fields from about 60 countries worldwide attended.

This content was produced with the assistance of AI translation services.